Comparison of the efficacy and safety of Empagliflozin and Dapagliflozin in uncontrolled type 2 diabetic patients
Keywords:
Type 2 Diabetes, Empagliflozin, DapagliflozinAbstract
The group (SGLT2)inh is the latest for the treatment of type 2 diabetes. It works by increasing the excretion of blood glucose in the urine and has a positive effect on the heart and kidneys. It reduces the pre- and post-load, improves glomerular filtration, affects blood volume, and reduces weight. The study included 150 patients with type 2 diabetes who were treated with one or more oral hypoglycemic agents and were not controlled. The patients were divided into two groups, the first was treated by a single dose of 25 mg of empagliflozin and the second by a single dose of 10 mg of dapagliflozin. They were followed up for 6 months. The aim of the study was to compare the control of HbA1c, PP2, FPG, weight reduction, and body mass index, and to study the effect of blood lipids and side effects between the two groups. The study demonstrated the effectiveness of the two drugs in reducing fasting and post-meal blood sugar and glycated hemoglobin with statistically significant values, with greater effectiveness for empagliflozin (p-value=0.002/p-value=0.0001/p-value=0.0001). Both reduced weight and body mass index, with greater effectiveness for empagliflozin (p-value=0.3/p-value=0.09). Both drugs were effective in reducing triglycerides and total cholesterol, with greater effectiveness for empagliflozin (p-value=0.4/p-value=0.8). Both increased HDL, with greater effectiveness for dapagliflozin (p-value=0.7), and contributed to reducing LDL, with greater effectiveness for empagliflozin (p-value=0.07). No serious side effects appeared except for urinary tract infections, with a greater rate for dapagliflozin
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.